vs

Side-by-side financial comparison of STONERIDGE INC (SRI) and Vertex, Inc. (VERX). Click either name above to swap in a different company.

STONERIDGE INC is the larger business by last-quarter revenue ($205.2M vs $196.6M, roughly 1.0× Vertex, Inc.). On growth, Vertex, Inc. posted the faster year-over-year revenue change (11.1% vs -6.0%). Vertex, Inc. produced more free cash flow last quarter ($7.7M vs $2.6M). Over the past eight quarters, Vertex, Inc.'s revenue compounded faster (10.5% CAGR vs -7.4%).

Stoneridge Inc is a global designer and manufacturer of advanced electrical and electronic components, integrated systems, and sensor solutions. It serves automotive, commercial vehicle, off-highway, and aerospace sectors, delivering products that boost vehicle safety, efficiency, connectivity, and environmental performance across key global markets.

Vertex Pharmaceuticals Incorporated is an American biopharmaceutical company based in Boston, Massachusetts. It was one of the first biotech firms to use an explicit strategy of rational drug design rather than combinatorial chemistry. It maintains headquarters in Boston, Massachusetts, and three research facilities, in San Diego, California, and Milton Park, Oxfordshire, England.

SRI vs VERX — Head-to-Head

Bigger by revenue
SRI
SRI
1.0× larger
SRI
$205.2M
$196.6M
VERX
Growing faster (revenue YoY)
VERX
VERX
+17.1% gap
VERX
11.1%
-6.0%
SRI
More free cash flow
VERX
VERX
$5.0M more FCF
VERX
$7.7M
$2.6M
SRI
Faster 2-yr revenue CAGR
VERX
VERX
Annualised
VERX
10.5%
-7.4%
SRI

Income Statement — Q4 FY2025 vs Q1 FY2026

Metric
SRI
SRI
VERX
VERX
Revenue
$205.2M
$196.6M
Net Profit
$-2.5M
Gross Margin
16.2%
63.5%
Operating Margin
-14.4%
31.1%
Net Margin
-1.3%
Revenue YoY
-6.0%
11.1%
Net Profit YoY
-122.6%
EPS (diluted)
$-2.76
$-0.02

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
SRI
SRI
VERX
VERX
Q1 26
$196.6M
Q4 25
$205.2M
$194.7M
Q3 25
$210.3M
$192.1M
Q2 25
$228.0M
$184.6M
Q1 25
$217.9M
$177.1M
Q4 24
$218.2M
$178.5M
Q3 24
$213.8M
$170.4M
Q2 24
$237.1M
$161.1M
Net Profit
SRI
SRI
VERX
VERX
Q1 26
$-2.5M
Q4 25
$-7.0M
Q3 25
$-9.4M
$4.0M
Q2 25
$-9.4M
$-961.0K
Q1 25
$-7.2M
$11.1M
Q4 24
$-67.8M
Q3 24
$-7.1M
$7.2M
Q2 24
$2.8M
$5.2M
Gross Margin
SRI
SRI
VERX
VERX
Q1 26
63.5%
Q4 25
16.2%
64.8%
Q3 25
20.3%
63.1%
Q2 25
21.5%
65.7%
Q1 25
21.2%
63.8%
Q4 24
19.5%
65.6%
Q3 24
20.8%
64.8%
Q2 24
22.7%
63.7%
Operating Margin
SRI
SRI
VERX
VERX
Q1 26
31.1%
Q4 25
-14.4%
-1.3%
Q3 25
-1.6%
2.2%
Q2 25
-1.1%
-2.1%
Q1 25
-1.5%
2.5%
Q4 24
-2.0%
-7.3%
Q3 24
0.1%
2.9%
Q2 24
1.4%
4.7%
Net Margin
SRI
SRI
VERX
VERX
Q1 26
-1.3%
Q4 25
-3.6%
Q3 25
-4.5%
2.1%
Q2 25
-4.1%
-0.5%
Q1 25
-3.3%
6.3%
Q4 24
-38.0%
Q3 24
-3.3%
4.2%
Q2 24
1.2%
3.2%
EPS (diluted)
SRI
SRI
VERX
VERX
Q1 26
$-0.02
Q4 25
$-2.76
Q3 25
$-0.34
Q2 25
$-0.34
Q1 25
$-0.26
Q4 24
$-0.22
Q3 24
$-0.26
Q2 24
$0.10

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
SRI
SRI
VERX
VERX
Cash + ST InvestmentsLiquidity on hand
$66.3M
$252.5M
Total DebtLower is stronger
$180.9M
Stockholders' EquityBook value
$179.8M
$246.5M
Total Assets
$551.2M
$1.2B
Debt / EquityLower = less leverage
1.01×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
SRI
SRI
VERX
VERX
Q1 26
$252.5M
Q4 25
$66.3M
$314.0M
Q3 25
$54.0M
$313.5M
Q2 25
$49.8M
$284.4M
Q1 25
$79.1M
$270.4M
Q4 24
$71.8M
$296.1M
Q3 24
$54.1M
$279.0M
Q2 24
$42.1M
$325.5M
Total Debt
SRI
SRI
VERX
VERX
Q1 26
Q4 25
$180.9M
$337.5M
Q3 25
$336.9M
Q2 25
$336.3M
Q1 25
$335.8M
Q4 24
$201.6M
$335.2M
Q3 24
$334.7M
Q2 24
$334.1M
Stockholders' Equity
SRI
SRI
VERX
VERX
Q1 26
$246.5M
Q4 25
$179.8M
$258.9M
Q3 25
$251.2M
$264.5M
Q2 25
$260.5M
$248.0M
Q1 25
$253.1M
$200.5M
Q4 24
$245.3M
$179.4M
Q3 24
$271.4M
$259.0M
Q2 24
$270.5M
$233.1M
Total Assets
SRI
SRI
VERX
VERX
Q1 26
$1.2B
Q4 25
$551.2M
$1.3B
Q3 25
$632.1M
$1.2B
Q2 25
$639.4M
$1.2B
Q1 25
$657.4M
$1.2B
Q4 24
$621.6M
$1.2B
Q3 24
$662.5M
$1.2B
Q2 24
$666.7M
$1.0B
Debt / Equity
SRI
SRI
VERX
VERX
Q1 26
Q4 25
1.01×
1.30×
Q3 25
1.27×
Q2 25
1.36×
Q1 25
1.67×
Q4 24
0.82×
1.87×
Q3 24
1.29×
Q2 24
1.43×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
SRI
SRI
VERX
VERX
Operating Cash FlowLast quarter
$8.8M
$38.0M
Free Cash FlowOCF − Capex
$2.6M
$7.7M
FCF MarginFCF / Revenue
1.3%
3.9%
Capex IntensityCapex / Revenue
3.0%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$12.2M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
SRI
SRI
VERX
VERX
Q1 26
$38.0M
Q4 25
$8.8M
$42.3M
Q3 25
$3.6M
$62.5M
Q2 25
$10.7M
$46.0M
Q1 25
$10.9M
$14.8M
Q4 24
$19.2M
$41.1M
Q3 24
$10.8M
$41.4M
Q2 24
$8.7M
$57.7M
Free Cash Flow
SRI
SRI
VERX
VERX
Q1 26
$7.7M
Q4 25
$2.6M
Q3 25
$-2.7M
Q2 25
$7.4M
Q1 25
$4.8M
Q4 24
$14.0M
Q3 24
$4.6M
$-24.3M
Q2 24
$1.5M
FCF Margin
SRI
SRI
VERX
VERX
Q1 26
3.9%
Q4 25
1.3%
Q3 25
-1.3%
Q2 25
3.3%
Q1 25
2.2%
Q4 24
6.4%
Q3 24
2.2%
-14.2%
Q2 24
0.6%
Capex Intensity
SRI
SRI
VERX
VERX
Q1 26
Q4 25
3.0%
Q3 25
3.0%
Q2 25
1.4%
Q1 25
2.8%
Q4 24
2.4%
Q3 24
2.9%
38.5%
Q2 24
3.0%
Cash Conversion
SRI
SRI
VERX
VERX
Q1 26
Q4 25
Q3 25
15.44×
Q2 25
Q1 25
1.33×
Q4 24
Q3 24
5.73×
Q2 24
3.11×
11.18×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

SRI
SRI

Control Devices$51.7M25%
Electronics$38.0M19%
EE$34.2M17%
SE$28.6M14%
NL$24.5M12%
Stoneridge Brazil$14.1M7%
Asia Pacific$13.1M6%

VERX
VERX

Software subscriptions$167.1M85%
Services$29.5M15%

Related Comparisons